Identifying immune system markers to predict treatment response in ovarian cancer
Official title: Defining tumor and blood-based immunogenomic signatures predicting response to immunotherapy in ovarian cancer
Funded at Icahn School of Medicine at Mount Sinai · NIH-10949078 · Data updated 2026-11-12
This study is looking at how certain genes and immune system markers can help doctors figure out which ovarian cancer patients are most likely to benefit from immunotherapy, so they can create more personalized treatment plans just for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $99,171 |
| NIH project number | 4K00CA274650-03 |
| Project ID | NIH-10949078 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are ovarian cancer patients who are considering or currently undergoing immunotherapy.
✕Less likely to help
Patients with early-stage ovarian cancer or those not eligible for immunotherapy may not benefit from this research.
What this research studies
This research investigates how specific genetic and immune system markers can predict which ovarian cancer patients will respond best to immunotherapy. By analyzing tumor and blood samples, the study aims to identify biomarkers that indicate the likelihood of a positive response to treatments that activate the immune system. The approach focuses on understanding the regulatory networks that influence T-cell activation, which are crucial for effective immunotherapy. Patients may have their immune profiles assessed to tailor treatment plans more effectively.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective immunotherapy treatments for ovarian cancer patients.
How similar studies have gone: Other research has shown promise in using genetic and immune markers to predict treatment responses in various cancers, indicating that this approach may be viable.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Monson, Kelsey R — Icahn School of Medicine at Mount Sinai
- Study coordinator: Monson, Kelsey R
Related research
Other NIH-funded projects on the same topics.
-
Next-Generation NK Cell Therapy for Ovarian Cancer
A cutting-edge, donor-derived natural killer (NK) cell therapy is being developed to treat ovarian cancer more safely and effectively than traditional CAR-T approaches.
-
Targeting PP4 to boost ovarian cancer response to immunotherapy
A Mayo Clinic study aims to see if inhibiting PP4 can make chemo-resistant ovarian cancer more responsive to immunotherapy.
-
Enhancing Cancer Immunotherapy for Resistant High-Grade Serous Ovarian Cancer with a New Platinum Nanotherapy
A new platinum-based nanotherapy is being tested to help women with chemoresistant high-grade serous ovarian cancer survive longer by boosting cancer-killing immune responses.
-
Next-generation engineered NK cell therapy for ovarian cancer
This project offers a new off-the-shelf NK cell treatment designed to attack ovarian cancer, especially disease that is resistant to platinum chemotherapy.
-
Improving ovarian cancer treatment with immunotherapy by targeting PP4
This project looks at how blocking a protein called PP4 might make immunotherapy work better for women with ovarian cancer.
-
Investigating a new immunotherapy approach for ovarian cancer
This study is testing a new treatment for advanced ovarian cancer that combines a special immune therapy with a vaccine to help your body fight the cancer better, and it’s looking for patients to see how well it works and if it’s safe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.